Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704024 · ClinicalTrials.gov registry record · Phase 3
Reducing Vertical Transmission of Hepatitis B in Africa
A Phase 3 study of Hepatitis B Infection, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 1
- Study location
NCT04704024 is a Phase 3 study of Hepatitis B Infection that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 450 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04704024, a Phase 3 study of Hepatitis B Infection, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the risk of hepatitis B transmission. The study will measure efficacy, safety, tolerability and adherence to medication.
Conditions Studied
Interventions
- DRUG Tenofovir Disoproxil Fumarate
- DRUG Lamivudine Oral Solution
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04704024
The ClinicalTrials.gov registry entry for NCT04704024 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis B Infection appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir Disoproxil Fumarate is the first listed.
NCT04704024 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT04704024 about?
NCT04704024 is a clinical study titled "Reducing Vertical Transmission of Hepatitis B in Africa". Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of...
What is the current status of trial NCT04704024?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2021-09-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04704024 study?
This clinical trial studies the following conditions: Hepatitis B Infection.
What interventions are being tested in trial NCT04704024?
The interventions under investigation include: Tenofovir Disoproxil Fumarate (DRUG), Lamivudine Oral Solution (DRUG).
Who is sponsoring clinical trial NCT04704024?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04704024 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
ACTIVE NOT RECRUITING
-
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.